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Dolutegravir-based regimen maintains virological success in a patient with archived mutations
to integrase inhibitors
Dolutegravir (DTG) is the latest integrase inhibitor (INI)
to be approved for the treatment of HIV-1 infection, with
a high antiviral effect, excellent efficacy and safety profile
[1,2]. Although DTG seems to show a high genetic
barrier, its resistance profile has not yet been established,
particularly in patients with failure on an INI-based
regimen [3]. The VIKING-3 study among patients with
INI-resistant virus reported that the maximum reduction
in DTG susceptibility occurred when Q148 was
accompanied by at least two other major mutations.
For these patients, the odds of achieving HIV-RNA less
than 50 copies/ml were 96% lower than those of patients
with no evidence of Q148 mutations, even when DTG
was dosed twice a day (BID) [4,5]. Moreover, the role of
archived integrase mutations is still unknown and
generally the clinical significance of drug resistance
mutations (DRMs) in proviral DNA remains contro-
versial. Several studies showed that DRMs in proviral
DNA may be implicated in therapy failure, whereas
others reported that genotypic resistance tests on
peripheral blood mononuclear cells (PBMCs) did not
provide useful information for assessing the risk of
virological failure [6–8].
Here, we describe the case of a successful treatment
obtained with a DTG-containing regimen in a 55-year-
old MSM, harboring mutations archived in PBMCs
conferring high-level resistance to the newer INI in the
presence of a multidrug class-resistant HIV-1 because of
more than 20 years’ antiretroviral therapy (ART).
The man has been living with HIV-1 (subtype B) since
1986, with a history of AIDS-defining events and prior
failure to four antiretroviral classes [nucleos(t)ide and
nonnucleoside reverse transcriptase inhibitors, protease
inhibitors, and fusion inhibitors]. He started a raltegravir
(RAL)-containing regimen in June 2013, but did not take
it on regular basis and failed to achieve a fully suppressed
viral load. One year later, resistance to INIs was detected
in plasma (E138A, G140S, Q148H); RAL was stopped
and since then his treatment has been modified several
times according to drug resistance and intolerance.
Because of persistent viremia, in February 2015,
genotypic resistance typing (GRT) was performed on
plasma and PBMCs, revealing the same mutations in both
integrase (IN) gene compartments. On the basis of GRT,
a therapeutic regimen containing rilpivirine and abaca-
vir/lamivudine was started. Viral load (VL) decreased
slightly thereafter, and in December 2015, another GRT
performed on plasma disclosed no major DRM in the IN
gene. Despite a previous INI failure, due to few
therapeutic options, the patient received DTG (BID),
emtricitabine and tenofovir disoproxil fumarate. A rapid
virological response was observed, and after 3 months,
HIV-RNA declined below 37 copies/ml. Viremia was
monitored every 12 weeks thereafter and became
undetectable after 9 months, whereas CD4þ T cells rose
from 120 to 653 cells/ml. In addition, after 1 year of
treatment, a GRT performed on HIV-DNA showed the
same INI resistance mutations found in 2014. The patient
currently maintains undetectable levels of VL.
To the best of our knowledge, this is the first report
describing virological success after 1 year of DTG treat-
ment in a patient with archivedDTG resistancemutations.
Furthermore, this report shows that the concordance
between viral compartments may differ profoundly under
the selective pressures exerted by antiretroviral drugs. We
found that the viral mutants had disappeared from the
plasma over time, whereas they persisted in PBMCs after
treatment interruption, perhaps due to the different rate of
virus turnover in these compartments [9,10]. Although the
rapid reappearance of DRMs has been hypothesized on
treatment reinitiation in the case of archivedmutations [8],
after more than 1 year from DTG start, our patient is
demonstrating excellent virological and immunological
responses despite the archived integrase DRM. These
findings may be due either to the fact that the HIV-1
genome is often defective in PBMCs after a long-term
ART [11], or the current follow-up is too short.
In conclusion, this case confirms that DTG is a potent
drug that allows complete viral suppression in a brief time,
even in ‘difficult patients’ with preexisting resistance to
INIs. It also suggests that archived DRMs either in plasma
and/or in DNA should not limit the use of DTG as a
salvage-treatment option. Future studies are needed to
better elucidate the mechanism of resistance to DTG, and
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to define guidelines for patients with archived mutations,
to minimize the risk of DRM emergence under
treatment pressure.
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